Combigan - a combination drug containing two active substances: brimonidine - an adrenergic agonist, which has a stimulating effect on alpha2 adrenergic receptors, and timolol - a beta adrenergic receptor blocker. Both active substances reduce intraocular pressure (IOP) due to the combined interaction, which leads to a more pronounced hypotensive effect compared to the effect of each component separately.
Brimonidine is an alpha-adrenergic receptor agonist, and has 1000-fold greater selectivity for alpha2-adrenergic receptors than for alpha1-adrenoreceptors. Selectivity is expressed in the absence of mydriasis and vasoconstriction of the microvasculature. The antihypertensive effect of brimonidine is provided by reducing the formation of intraocular fluid and increasing its flow along the uveoscleral pathway.
Timolol is a non-selective beta-adrenergic blocker. It does not possess endogenous sympathomimetic activity and membrane stability. Timolol reduces IOP by reducing the formation of fluid inside the eye. The exact mechanism of action has not been determined, and is likely related to inhibition of adenosine monophosphate (cAMP) synthesis and results from intrinsic stimulation of beta-adrenergic receptors.
Indications
Open angle glaucoma
Ocular hypertension (with insufficient effectiveness of topical treatment with beta-blockers).
to express
1 ml of eye drops solution contains:
Active ingredients:
Brimonidine tartrate - 2.0 mg/ml.
Timolol maleate - 6.8 mg/ml.
In terms of timolol - 5.0 mg/ml.
Excipients: benzalkonium chloride, sodium dihydrogen phosphate, heptahydrate, sodium dihydrogen phosphate monohydrate, hydrochloric acid, sodium hydroxide, water.
